---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095419"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:06:17.234193+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma Q2 cash $308.5M; ORIC-114 expansion and ORIC-944 combo dosing underway

## Summary
- Cash and investments $308.5M as of June 30, 2024; expected to fund operations into late 2026.
- R&D expenses $28.9M in Q2 2024 vs $18.8M Q2 2023, up $10.2M on pipeline advancement.
- G&A expenses $7.1M in Q2 2024 vs $6.2M Q2 2023, up $0.9M on higher personnel costs.
- ORIC-114 Phase 1b dose escalation complete; expansion cohorts in EGFR/HER2 mutant NSCLC dosed; data expected H1 2025.
- ORIC-944 combo dosing initiated with NUBEQA and ERLEADA; clinical trial agreements with Bayer and J&J.

## SEC filing metadata
- accession: 0000950170-24-095419
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017024095419/0000950170-24-095419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017024095419/oric-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095419
- JSON: https://secwatch.observer/filing/0000950170-24-095419.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.